Our Pricing

Wegovy Maintenance After Goal Weight: Starter Guide

Published on: June 03, 2026

Achieving your goal weight on Wegovy is a significant milestone, but understanding wegovy maintenance after goal weight is crucial for long-term success. At Cured Pharmacy, our UK-registered clinical team helps patients transition to sustainable maintenance strategies, with transparent pricing from £79.00 and ongoing prescriber support to prevent weight regain.

Understanding Wegovy Maintenance After Goal Weight

When you reach your target weight on Wegovy (semaglutide 2.4mg), the question isn't whether to stop immediately, but how to maintain your results long-term. Clinical evidence from the STEP trials demonstrates that semaglutide works by reducing appetite through GLP-1 receptor activation, and discontinuing treatment abruptly often leads to weight regain [1].

In the STEP 4 trial, participants who stopped semaglutide after 20 weeks of treatment regained approximately two-thirds of their lost weight over the following 48 weeks, whilst those who continued maintenance dosing sustained their weight loss [1]. This data underscores the importance of a structured maintenance approach rather than immediate cessation.

Your UK prescriber will assess your individual circumstances, including how quickly you reached your goal weight, your metabolic response to treatment, and any underlying health conditions. Maintenance strategies may include continuing your current dose, adjusting to a lower maintenance dose, or implementing a structured tapering schedule subject to clinical assessment.

Wegovy Maintenance Dose Options for UK Patients

The standard maintenance dose of Wegovy is 2.4mg once weekly, which is the dose used in clinical trials showing sustained weight loss over 68 weeks [2]. However, some patients may achieve adequate weight maintenance on lower doses, particularly if they experienced significant side effects at the maximum dose.

UK prescribers may consider maintenance dosing strategies between 1.0mg and 2.4mg weekly, depending on your response to treatment. Clinical data suggests that even the 1.7mg dose maintains meaningful weight loss compared to discontinuation, though the 2.4mg dose typically provides optimal results [2].

It's essential to note that dosing decisions must be made by a UK-registered prescriber following clinical assessment. At Cured Pharmacy, our clinical team reviews your weight maintenance progress during follow-up consultations to determine the most appropriate long-term dosing strategy for your individual needs.

Adjusting Your Maintenance Dose

If you're maintaining your goal weight comfortably on 2.4mg but experiencing persistent gastrointestinal side effects, your prescriber may trial a reduction to 1.7mg for 4-8 weeks whilst monitoring your weight stability. Any dose adjustment should be gradual and medically supervised to minimise the risk of weight regain.

How Long Should You Stay on Wegovy After Reaching Goal Weight?

Clinical trial data extends to 68 weeks of continuous semaglutide treatment, demonstrating sustained weight loss throughout this period without plateau [2]. However, obesity is recognised by NICE and the MHRA as a chronic condition requiring long-term management, similar to hypertension or type 2 diabetes.

Many UK patients continue Wegovy maintenance indefinitely to prevent weight regain, particularly those with obesity-related comorbidities such as type 2 diabetes, hypertension, or sleep apnoea. The STEP 5 trial followed participants for up to 104 weeks, showing continued weight maintenance with ongoing treatment [3].

Your prescriber will conduct regular reviews every 3-6 months to assess whether continued treatment remains clinically appropriate. Factors considered include weight stability, side effect profile, improvement in obesity-related health markers, and your ability to maintain lifestyle modifications alongside medication.

Stopping Wegovy: What to Expect

If you and your prescriber decide to discontinue Wegovy, expect that appetite regulation will gradually return to pre-treatment levels over 4-8 weeks as semaglutide clears your system. Clinical trials show that without ongoing lifestyle support, most patients regain weight after stopping GLP-1 receptor agonists [1]. A structured tapering plan combined with dietetic support may help minimise regain, though this remains an area of ongoing research.

Preventing Weight Regain After Wegovy Goal Weight

Maintaining weight loss after reaching your goal requires a multi-faceted approach combining continued medication (if clinically appropriate), dietary modifications, physical activity, and behavioural strategies. Research consistently shows that pharmacological support significantly improves long-term weight maintenance compared to lifestyle interventions alone [3].

Key strategies include maintaining a structured eating pattern with regular meal times, prioritising protein intake (1.2-1.6g per kg body weight), engaging in at least 150 minutes of moderate-intensity activity weekly, and monitoring your weight regularly to detect early regain. Many patients find that continuing Wegovy maintenance dosing makes these lifestyle modifications more sustainable by reducing hunger and food preoccupation.

At Cured Pharmacy, we recommend discussing your maintenance plan with your prescriber before reaching your goal weight, allowing time to establish sustainable habits whilst still benefiting from appetite suppression. Our clinical team can provide ongoing support and dose adjustments as needed, with transparent pricing from £79.00 per prescription.

Wegovy Maintenance vs Stopping: Clinical Evidence

The STEP 4 withdrawal trial provides the most robust evidence comparing maintenance versus discontinuation. Participants who had achieved 10.6% weight loss after 20 weeks on semaglutide 2.4mg were randomised to either continue treatment or switch to placebo for 48 weeks [1].

Those continuing semaglutide lost an additional 7.9% body weight, whilst those switched to placebo regained 6.9% of their body weight. This 14.8 percentage point difference demonstrates the significant role of continued pharmacological support in weight maintenance [1].

Beyond weight outcomes, the maintenance group showed sustained improvements in cardiometabolic markers including HbA1c, systolic blood pressure, and lipid profiles, whilst these benefits diminished in the discontinuation group. This evidence supports the position that obesity requires ongoing treatment rather than short-term intervention.

Real-World Maintenance Outcomes

Whilst clinical trials provide controlled conditions, real-world data from UK prescribing patterns suggests that patients who continue maintenance dosing for at least 12 months post-goal weight have significantly better outcomes than those who discontinue within 6 months. Individual results vary based on adherence, lifestyle factors, and metabolic differences, and all patients require ongoing clinical monitoring.

Starting Your Wegovy Maintenance Plan at Cured Pharmacy

If you're approaching or have reached your goal weight on Wegovy, our UK-registered clinical team can assess your suitability for maintenance dosing through a free online consultation taking under 3 minutes. We provide genuine UK-licensed Wegovy pens with transparent upfront pricing from £79.00, significantly lower than typical market rates.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all prescribing decisions, ensuring you receive expert guidance tailored to your individual circumstances. All consultations are conducted by UK-registered prescribers, and we never dispense prescription medications without proper clinical assessment.

To begin your maintenance plan, complete our online assessment which covers your weight loss journey, current dose, goal weight achievement, side effect profile, and long-term objectives. Your prescriber will review your submission and determine the most appropriate maintenance strategy, whether that's continuing your current dose, adjusting to a lower maintenance dose, or implementing a structured review schedule.

Scientific References

1. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or adjusting your current treatment plan.